Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Other(1)

Detailed Status

Suspended1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (50.0%)
Phase 41 (50.0%)

Trials by Status

suspended150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_1

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

NCT05408312
suspendedphase_4

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

NCT05165732

Clinical Trials (2)

Showing 2 of 2 trials
NCT05408312Phase 1

Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

Completed
NCT05165732Phase 4

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19

Suspended

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2